Amylyx CEO Cohen gains 60K shares in PSU vesting

Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Joshua B. Cohen received an equity award linked to company performance.

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Joshua B. Cohen received an equity award linked to company performance. On August 18, 2026, he acquired 60,039 shares of Common Stock represented by performance share units (PSUs) that vested on that date upon achievement of specified performance metrics. Following this vesting event, Cohen directly holds 3,643,587 shares of Amylyx Common Stock.

Insider Trade Summary

Grant/Award: 60,039 shares

Grant/Award 1 txn

Insider Cohen Joshua B

Role Co-Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	60,039	$0.00	$0.00

Holdings After Transaction: Common Stock — 3,643,587 shares (Direct)

Footnotes (1)

1. F1. The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.

Key Figures

Shares acquired in award: 60,039 shares of Common Stock Price per share for award: $0.00 per share Total shares held after transaction: 3,643,587 shares of Common Stock +2 more

5 metrics

Shares acquired in award 60,039 shares of Common Stock Performance share units vesting on August 18, 2026

Price per share for award $0.00 per share Grant/award acquisition of Common Stock represented by PSUs

Total shares held after transaction 3,643,587 shares of Common Stock Direct ownership by Joshua B. Cohen following PSU vesting

Transaction date August 18, 2026 Vesting date for performance share units and share acquisition

Number of acquire-type transactions 1 transaction Form 4 transaction summary for this filing

Key Terms

performance share units, PSUs, vested, grant/award acquisition

4 terms

performance share units financial

"The reported shares are represented by performance share units, or PSUs"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

PSUs financial

"represented by performance share units, or PSUs, and were awarded"

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

vested financial

"Shares subject to the PSU vested on August 18, 2026"

grant/award acquisition financial

"transaction_action":"grant/award acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AMLX report for Joshua B. Cohen on this Form 4?

Joshua B. Cohen was reported to have acquired 60,039 shares of Amylyx Common Stock on August 18, 2026, through a grant classified as a performance-based equity award represented by performance share units (PSUs) that vested on that date.

How many AMLX shares does Joshua B. Cohen hold after this transaction?

After the August 18, 2026 PSU vesting, Joshua B. Cohen directly holds 3,643,587 shares of Amylyx Pharmaceuticals, Inc. Common Stock, as reported in the Form 4 filing.

What type of security was involved in Joshua B. Cohen’s AMLX Form 4 transaction?

The transaction involved Common Stock of Amylyx Pharmaceuticals, Inc., represented by performance share units (PSUs) that converted into shares upon satisfaction of certain performance metrics and vested on August 18, 2026.

Was the August 18, 2026 AMLX insider award a cash transaction?

No. The Form 4 reports a grant/award acquisition of 60,039 shares at a per-share transaction price of $0.00, reflecting a performance-based equity award rather than a market purchase for cash.

What triggered the vesting of Joshua B. Cohen’s performance share units at AMLX?

The filing states that the reported shares are represented by PSUs that were awarded upon achievement of certain performance metrics, and that the shares subject to the PSU vested on August 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2026 - 09:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Joshua B

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		A		60,039(1)	A	$0	3,643,587	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.

	/s/ Joshua B. Cohen	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)